Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Thoracic Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1498524
This article is part of the Research Topic Early-Onset Lung Cancer: Global Trends, Disparities, and Personalized Treatment Strategies View all articles

Characterizing Microbial Communities and Their Correlation with Genetic Mutations in Early-Stage Lung Adenocarcinoma: Implications for Disease Progression and Therapeutic Targets

Provisionally accepted
Haoshuai Yang Haoshuai Yang Jin Zhang Jin Zhang Hongxiang Feng Hongxiang Feng *Fei Qi Fei Qi *Fanjia Kong Fanjia Kong *Weijie Zhu Weijie Zhu *Chaoyang Liang Chaoyang Liang Zhenrong Zhang Zhenrong Zhang *
  • China-Japan Friendship Hospital, Beijing, Beijing Municipality, China

The final, formatted version of the article will be published soon.

    Background:Lung adenocarcinoma (LUAD), the most prevalent form of lung cancer.The transition from adenocarcinoma in situ (AIS), and minimally invasive adenocarcinoma (MIA) to invasive adenocarcinoma (IAC) is not fully understood.Intratumoral microbiota may play a role in LUAD progression, but comprehensive stage-wise analysis is lacking.Methods:Tumor and bronchoalveolar lavage fluid (BALF) samples from patients with AIS/MIA or IAC were collected for next-generation sequencing to characterize microbial diversity and composition. DNA extraction involved lysing samples with nuclease and protease, followed by homogenization and elution. Sequencing libraries were prepared and sequenced on the Illumina platform. Whole exome sequencing was performed to identify somatic mutations and genetic variants. Bioinformatics analysis, including taxonomic annotation with Kraken2 and de novo assembly with MEGAHIT, was conducted to process metagenomic data. Correlation analysis was performed to link microbial species with mutated genes using custom R scripts.Results: Metagenomic analysis revealed a distinct microbial profile in IAC compared to AIS/MIA, with increased abundance of Bacteroidetes and Firmicutes in the IAC group. Bosea sp. and Microbacterium paludicola, were less abundant in IAC, suggesting a potential protective role in early-stage disease. Conversely, Mycolicibacterium species were more prevalent in IAC, indicating a possible contribution to disease progression. Genetic sequencing identified PTPRZ1 strongly correlating with microbial composition, suggesting a mechanistic link between microbiota and genetic alterations in LUAD.This study characterizes microbial communities in various stages of LUAD, revealing links between microbiota and genetic mutations. The unique microbiota suggests its role in LUAD progression and as a therapeutic target.

    Keywords: Lung Adenocarcinoma, tumor microbiome, PTPRZ1, Next-generation sequencing, therapeutic targets

    Received: 19 Sep 2024; Accepted: 13 Dec 2024.

    Copyright: © 2024 Yang, Zhang, Feng, Qi, Kong, Zhu, Liang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Hongxiang Feng, China-Japan Friendship Hospital, Beijing, 100029, Beijing Municipality, China
    Fei Qi, China-Japan Friendship Hospital, Beijing, 100029, Beijing Municipality, China
    Fanjia Kong, China-Japan Friendship Hospital, Beijing, 100029, Beijing Municipality, China
    Weijie Zhu, China-Japan Friendship Hospital, Beijing, 100029, Beijing Municipality, China
    Zhenrong Zhang, China-Japan Friendship Hospital, Beijing, 100029, Beijing Municipality, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.